Transmission of vaccinia virus and rationale for measures for prevention

Clinical Infectious Diseases

Volumn 37, Issue 2, 2003, Pages 281-284

  Lane, J Michael ^a,d,e   Fulginiti, Vincent A ^b,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c Children's Hospital Colorado   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMALLPOX VACCINE;

AIRBORNE INFECTION; DISEASE ASSOCIATION; DISEASE TRANSMISSION; HEALTH CARE PERSONNEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; MEMBRANE PERMEABILITY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SKIN DEFECT; SKIN INFECTION; SMALLPOX; VACCINATION; VACCINIA VIRUS; VIRUS SHEDDING; VIRUS TRANSMISSION; WOUND DRESSING; ARTICLE; CHEMICALLY INDUCED DISORDER; METHODOLOGY; PHYSIOLOGY; PREVENTIVE HEALTH SERVICE; VACCINIA;

HEALTH PERSONNEL; HUMANS; IMMUNIZATION PROGRAMS; SMALLPOX; SMALLPOX VACCINE; VACCINIA; VACCINIA VIRUS;

EID: 0041766686     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/377236     Document Type: Review

References (18)

1. Stevenson RW, Stolberg SG. Bush lays out plan on smallpox shots; military is first. New York Times, 14 December 2002:A1.
2. Neff JM, Lane JM, Fulginiti VA, Henderson DA. Contact vaccinia - transmission of vaccinia from smallpox vaccination, JAMA 2002; 288:1901-5.
3. Sepkowltz KA. Current concepts: how contagious is vaccinia? N Engl J Med 2003; 348:439-46.
4. Wharton M, Strikas RA, Harpaz R, et al. Recommendations for using smallpox vaccine in a pre-event vaccination program: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (H1CPAC). MMWR Recomm Rep 2003; 52(RR-7):1-16.
5. Cooney EL, Collier AC, Greenberg PD, et al. Safety and immunological response to a recombinant vaccinia virus expressing HIV envelope glycoprotein. Lancet 1991; 337:567-72.
6. Friedman RM, Baron S, Buckler CE, Steinmuller RI. The role of antibody, delayed hypersensitivity, and interferon production in recovery of guinea pigs from primary infection with vaccinia virus. J Exp Med 1962; 116:347-56.
7. Koplan JP, Marton KI. Smallpox vaccination revisited: some observations on the biology of vaccinia. Am J Trop Med Hyg 1975; 24:656-63.
8. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: national surveillance in the United States. N Engl J Med 1969; 281:1201-8.
9. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970; 122:303-9.
10. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox vaccine and vaccination in the intensified smallpox eradication program. In: Smallpox and its eradication. Geneva: World Health Organization, 1988:540-92.
11. Blattner RJ, Norman JO, Heys FM, Aksu I. Antibody response to cutaneous inoculation with vaccinia virus: viremia and viruria in vaccinated children. J Pediatr 1964; 64:839-52.
12. Kempe CH. Studies on smallpox and complications of smallpox vaccination. Pediatrics 1960; 26:176-89.
13. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. The pathogenesis, pathology, and immunology of smallpox and vaccinia. In: Smallpox and its eradication. Geneva: World Health Organization, 1988:122-67.
14. Fulginiti VA, Kempe CH, Hathaway WE, et al. Progressive vaccinia in immunologically deficient individuals. Birth Defects 1968; 5:129-51.
15. Wehrle PF, Posch J, Richter KH, Henderson DA. An airborne outbreak of smallpox in a German hospital and its significance with respect to other outbreaks in Europe. Bull World Health Organ 1970; 43:669-79.
16. Gurvich EB, Braginskaya VP, Shenkman LS, Sokolova AF, Davydova AV. Isolation of vaccinia virus from the pharynx of children vaccinated against smallpox. J Hyg Epldemiol Microbiol Immunol 1974; 18:69-76.
17. Cono J, Casey CG, Bell DM. Smallpox vaccination and adverse events: guidelines for clinicians. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52(RR-4):1-28.
18. Graham BS, Belshe RB, Clements ML, et al. Vaccination of vaccinianaïve adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J Infect Dis 1992; 166:244-52.